Navigation Links
Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections
Date:11/24/2008

--PS-Targeting AntibodiesMay Represent a Completely New Class of Drugs with Broad Potential to Treat Life-Threatening Viral Infections--

--Peregrine's Clinical-Stage Anti-PS Agent Bavituximab and Equivalent Antibodies Cured Lethal Viral Infections in Preclinical Models--

--Data Confirms PS is a 'Druggable' Target Common to a Number of Serious Viral Infections--

TUSTIN, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.

Bavituximab is in clinical trials for the treatment of hepatitis C virus (HCV) infection and in preclinical development for the treatment of viral hemorrhagic fevers under a contract worth up to $44.4 million with the bioterrorism program of the U.S. Defense Threat Reduction Agency (DTRA). Bavituximab and other anti-PS antibodies are also being studied preclinically in HIV, cytomegalovirus (CMV) and other serious viral infections.

"Based on these findings, anti-PS antibodies such as bavituximab may represent a completely new class of drugs for the treatment of life-threatening viral infections," said study co-author Dr. Philip Thorpe, professor of pharmacology at UT Southwestern Medical Center and a scientific advisor to Peregrine. "By targeting a property of the host cell rather than the virus itself, anti-PS antibodies have the potential to treat a range of viral infections, and they should be less susceptible to the viral mutations that contribute to the development of drug resistance."

In the research reported today, scientists at UT Southwestern assessed the activity of bavituximab in animal
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. First Study of War-Related Mental Disorders Among Iraqis 10 Years Post-Gulf War Published by Researchers at Wayne State University and Basrah University, Iraq
2. Long-Term Results of VisionCares Implantable Telescope for End-Stage Macular Degeneration Published in the American Journal of Ophthalmology
3. Results From Pre-Election Surveys Published in NEJM Show Deep Concerns About State of Health Care With McCain and Obama Supporters Differing Sharply on Directions for New Administration
4. Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
5. International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer
6. MultiVu Video Feed: NEW RESEARCH PUBLISHED IN THE AMERICAN JOURNAL OF CLINICAL NUTRITION FINDS PISTACHIOS IMPROVE RISK FACTORS FOR HEART DISEASE
7. McCulley/Cuppan Consultants Contribute Chapter to the Newly Published Book, Rhetoric of Healthcare: Essays Toward a New Disciplinary Inquiry
8. Notice of Proposed Rulemaking on U.S. Department of Labors Risk Assessment Procedures Published in Federal Register
9. Positive Findings Published on Emergent Technology for Treating Chronic Pain
10. Study Published in JAMA on RFID Interference Ignores Real-World Use Cases, According to SkyeTek
11. Data Published in Anticancer Research Show ChemoFx(R) Assay Results Correlate With Outcomes in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... NEW YORK (PRWEB) , ... August 31, 2015 , ... ... for anti-aging products for men and barbershops are scrambling to meet it. , Reports ... get information for hairstyles and haircare. But the data also reflects that men are ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... for physicians and allied health professionals dedicated to using lifestyle as a ... the establishment of the Lifestyle Medicine Lifetime Achievement and Trailblazer Awards, with ...
(Date:8/31/2015)... ... August 31, 2015 , ... Westchester Insurance, a full service ... up with the Tarrant County chapter of Meals on Wheels to provide healthy ... oldest and largest national organization that supports the more than five thousand nutrition ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based ... with Bright Pink® to raise money and awareness for breast and ovarian health. ... Hot Pink Sassy incandescent Mood-lite sold to Bright Pink® to encourage households, dorms, ...
(Date:8/31/2015)... ... ... There’s big news for ZendyHealth , a Los Angeles-based startup company ... health plans (CDHPs) are a growing phenomenon, and ZendyHealth has brought on two experts ... another to answer customers’ questions directly. , John Young, CEO of Consumerdriven, LLC will ...
Breaking Medicine News(10 mins):Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 2Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 3Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3Health News:Westchester Insurance and the Meals on Wheels Association Announce Joint Charity Effort to Provide Nutritious Meals for Senior Citizens 2Health News:Westchester Insurance and the Meals on Wheels Association Announce Joint Charity Effort to Provide Nutritious Meals for Senior Citizens 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3
... magazine has reported that cancer patients have been buying an untried ... illness//. The drug called DCA, short form for dichlroacetate has been ... has not been tested in humans so far. ,Understandably, ... in humans and it has been reported that around two hundred ...
... 29 (DPA) A Serbian patient has survived more than a ... Belgrade daily Blic reported Thursday.// ,The gauze was ... a spokesman of the Sremska Kamenica cardiovascular institute, 70 km ... ,It was found during surgery in mid-March. The latter operation ...
... millions of Americans whose vision is slowly ebbing due to ... may be riding to the rescue. ,In a ... stem cells have been shown to protect the vision of ... diseases that afflict humans. The new study appears today (March ...
... found mainly in partially hydrogenated vegetable oils and widely ... an increased risk of coronary heart disease (CHD). ... use in restaurants, and other cities are considering similar ... Public Health (HSPH) provides the strongest association to date ...
... Patricia Hewitt, the health secretary said that computer based ... depression and anxiety//. This will be available to all ... programs- Fear fighter and Beating the blues have been ... However, health experts have warned that computer aided programs ...
... can do more than making you look like one. It steers ... are a woman//, say researchers. , The report published ... by lead author Dr. David W. Dunstan and team from the ... data from people who confessed to sedentary lives ruled by lots ...
Cached Medicine News:Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 2Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 3Health News:Higher Trans Fat Levels in Blood Associated With Elevated Risk of Heart Disease 2Health News:Computer Based Therapy For Depression 2Health News:Sedentary Lives Equal Shorter ‘sweeter’ Liv 2
(Date:8/31/2015)... Mich. , Aug. 31, 2015  Diplomat Pharmacy, Inc. ... has announced that Phil Hagerman , Chairman & CEO, ... upcoming investor conferences. Mr. Hagerman and Mr. ... Healthcare Conference in Boston on Wednesday, ... Hagerman and Mr. Whelan are also scheduled to participate in ...
(Date:8/31/2015)... Aug. 31, 2015  Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today it has completed enrollment of the ... Committee (DRC) earlier this year, into the company,s ... first-in-class innate defense regulator (IDR) and is being ...
(Date:8/31/2015)... LAKE, N.J. and STAMFORD, Conn. ... U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue ... a worldwide collaboration agreement for the development and commercialization ... dual orexin receptor antagonist entering Phase III clinical development ... the terms of the agreement, Eisai and Purdue Pharma ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
... NEW YORK, Nov. 15, 2011 Reportlinker.com ... is available in its catalogue: ... East Asia ... analysis of four pharmaceutical markets that present ...
... SuccessEHS Director of Client Services Elizabeth Pharo will serve as ... This breakout session on Nov. 17 will highlight concrete examples ... have led to care improvements. The panel session is part ... Information Technology (ONC) Annual Meeting that will take place Nov. ...
Cached Medicine Technology:The Outlook for Pharmaceuticals in North East Asia 2The Outlook for Pharmaceuticals in North East Asia 3The Outlook for Pharmaceuticals in North East Asia 4SuccessEHS Director of Client Services to Serve as Panelist at ONC Annual Meeting 2SuccessEHS Director of Client Services to Serve as Panelist at ONC Annual Meeting 3
... a two chain (alpha- and beta-subunits) glycoprotein ... the placenta and is normally found in ... the trophoblastic epithelium of the placenta, hCG ... the early stages of pregnancy. The primary ...
... for movement is critical ... wheelchairs. Thats why this ... technology to do just ... state-of-the-art technology, these wheelchair ...
When patients are less mobile our ProPlus™ Stand-On Scale with built-in wheels moves easily to them. Extremely durable and safe, the easy grip handrail and non-skid platform provide added suppo...
... 100 provides a new screening, diagnostic, treatment ... medical management of sleep-related breathing disorders. The ... unmet need for an ambulatory, reliable, patient ... to the great number of OSA sufferers, ...
Medicine Products: